REFERENCES
- Mehta RL, Pascual MT, Soroko S, Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int. 2004;66(4):1613–1621.
- Ympa YP, Sakr Y, Reinhart K, Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med. 2005;118(8):827–832.
- Sanabria M, Munoz J, Trillos C, Dialysis outcomes in Colombia (DOC) study: A comparison of patient survival on peritoneal dialysis vs hemodialysis in Colombia. Kidney Int Suppl. 2008;73(108):S165–S172.
- Song JH, Humes HD. Renal cell therapy and beyond. Semin Dial. 2009;22(6):603–609.
- Humes HD, Weitzel WF, Fissell WH. Renal cell therapy in the treatment of patients with acute and chronic renal failure. Blood Purif. 2004;22(1):60–72.
- Inagaki M, Yokoyama TA, Sawada K, Prevention of LLC-PK1 cell overgrowth in a bioartificial renal tubule device using a MEK inhibitor, U0126. J Biotechnol. 2007;132(1):57–64.
- Humes HD, MacKay SM, Funke AJ, Tissue engineering of a bioartificial renal tubule assist device: In vitro transport and metabolic characteristics. Kidney Int. 1999;55(6):2502–2514.
- Kuriyama S, Tomonari H, Yoshida H, Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77(2):176–185.
- Navarro JF. In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrol Dial Transplant. 2003;18(11):2222–2226.
- Alexander M, Kewalramani R, Agodoa I. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin. 2007;23(12):2997–3008.
- Patel NS, Sharples EJ, Cuzzocrea S, Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004;66(3):983–989.
- Mujais SK, Beru N, Pullman TW, Erythropoietin is produced by tubular cell of the rat kidney. Cell Biochem Biophys. 1999;30:153–166.
- Gouva C, Nikolopoulos P, Ioannidis JP, Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004;66(2):753–760.
- Arcasoy MO. The non-hematopoietic biological effects of erythropoietin. Br J Hematol. 2008;141(1):14–31.
- Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res. 2004;63(2):208–216.
- Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6(6):484–494.
- Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55(3):808–820.
- Wang W, Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol. 2008;588(2–3):135–140
- Johnson DW, Pat B, Vesey DA, Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006;69(10):1806–1813.
- Nikolovski J, Gulari E, Humes HD. Design engineering of a bioartificial renal tubule cell therapy device. Cell Transplant. 1999;8(4):351–364.
- Song JH, Humes HD. The bioartificial kidney in the treatment of acute kidney injury. Curr Drug Targets. 2009;10(12):1227–1234.
- Joannidis M. Continuous renal replacement therapy in sepsis and multisystem organ failure. Semin Dial. 2009;22(2):160–164.
- Combarnous F, Tetta C, Cellier CC, Albumin loss in on-line hemodiafiltration. Int J Artif Organs. 2002;25(3):203–209.
- Saito A, Aung T, Sekiguchi K, Present status and perspectives of bioartificial kidneys. J Artif Organs. 2006;9(3):130–135.
- Ding F, Humes HD. The bioartificial kidney and bioengineered membranes in acute kidney injury. Nephron Exp Nephrol. 2008;109(4):e118–e122.